

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Shanghai Henlius Biotech, Inc. (the “**Company**”) dated 17 November 2022 (the “**Announcement**”) in relation to the connected transactions and continuing connected transactions in relation to the License Agreement. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

As stated in the Announcement, a circular (the “**Circular**”) containing further information regarding the transaction is expected to be despatched to the Shareholders on or about 1 December 2022. As additional time is required to finalise certain information to be included in the Circular, the Company expects the despatch of the Circular will be postponed to a date falling on or about 9 December 2022.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 1 December 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.